
|Articles|February 1, 2003
FDA clinical trial: Myopia study shows benefits of wavefront-guided ablations
Orlando-Six-month results from an FDA clinical trial indicate that customized wavefront-guided LASIK for treatment of myopia with the WavePrint system (VISX) is associated with safe and effective outcomes exceeding FDA targets. The wavefront-guided LASIK is also effective for minimizing increases in higher-order aberrations that can accompany conventional LASIK.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Study identifies 6 key genes linking air pollution to dry eye disease
5


















































.png)


